Lin BioScience, Inc.

銵?鋆蔭?詨

FIRST-IN-CLASS

DRUG TREATMENTS

Lin BioScience is focused on discovering and developing innovative
drug candidate for the treatment of cancer and eye diseases

ORAL DRUG TREATMENT

for MACULAR DEGENERATION

First-in-Class oral therapeutic candidate for Dry Age-related Macular Degeneration and Stargardt Disease

TARGET THERAPY

with BROAD ONCOLOGY APPLICATIONS

Natural small molecular inhibitor for treatment of broad variety of cancers

NEWS

Apr 24 , 2019 Belite Bio Announces FDA Approval of Investigational New Drug (IND) for Phase 1 Clinical Trial of LBS-008 to Treat Macular Degeneration and Stargardt Disease U.S. Food and Drug Administration has approved its Investigational New Drug application for LBS-008 (BPN-14967), a first-in-class oral therapy for the treatment of atrophic Age-related Macular Degeneration and Stargardt disease.

Oct 02 , 2018 Belite Bio Initiates Phase 1 Study of LBS-008 in Australia LBS-008 first-in-human phase 1 study is being conducted in healthy volunteers in Australia and is expected to be completed during the 2nd half of 2019.

Sep 18 , 2018 FDA Grants Lin BioScience Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Disease Designation enhances FDA orphan drug designation for Phase I candidate targeting incurable blindness in children.

THERAPEUTIC AREAS